Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will present a corporate presentation at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026 in San Francisco.
Presentation details: Date: January 11, 2026; Time: 1:20 PM PT; Presenter: Laxminarayan Bhat, Ph.D.; Location: Marines’ Memorial Club, San Francisco, CA.
Positive
- None.
Negative
- None.
News Market Reaction – RVPH
In the Dec 29 session, RVPH declined 5.44%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.7% during that session. Argus tracked a trough of -7.5% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Regulatory update | Negative | -45.5% | FDA asked for a second Phase 3 brilaroxazine trial before NDA filing. |
| Nov 13 | Earnings and update | Positive | -6.6% | Q3 2025 results, positive OLE data, and capital raises alongside NDA planning. |
| Nov 12 | Data presentation | Positive | +3.3% | Neuroscience 2025 presentation on anti‑inflammatory effects of brilaroxazine. |
| Nov 10 | Patent grant | Positive | +9.1% | European patent granted for brilaroxazine use in pulmonary fibrosis. |
| Oct 29 | Investor conference | Neutral | +1.7% | Participation in Spartan Capital investor conference to highlight the story. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent major clinical and regulatory updates have triggered large directional moves, with the negative FDA feedback on brilaroxazine prompting the sharpest selloff, while positive IP and data presentations saw supportive but smaller gains.
Over the last few months, Reviva has reported several material milestones. A Dec 23, 2025 FDA regulatory update on brilaroxazine required a second Phase 3 trial, and the stock fell 45.54%. Earlier, Q3 2025 results on Nov 13, 2025 included a net loss of $4.0M, cash of $13.2M, and recent equity raises. November also brought new schizophrenia and anti‑inflammatory data presentations and a European patent for pulmonary fibrosis, which produced modestly positive reactions. An investor conference on Oct 29, 2025 had a small upside impact. Today’s forum presentation fits into this pattern of ongoing visibility efforts alongside pivotal regulatory and financing needs.
Key Terms
central nervous system medical
cns medical
cardiometabolic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA.
Presentation Details:
Format: Corporate Presentation
Date: Sunday, January 11, 2026
Time: 1:20 PM PT
Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location: Marines’ Memorial Club, San Francisco, CA
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
